You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Additional costs related to formulation, chronic tox and general development of PTI-125
SBC: PAIN THERAPEUTICS, INC. Topic: NIAProject Summary Abstract PTIis a novel small molecule AD therapeutic candidate with a novel target and mechanism of actionPTIbinds and reverses an altered conformation of the scaffolding protein filamin AFLNAto prevent Aandapos s tight binding to and toxic signaling via thenicotinic acetylcholine receptornAChRas well as Aandapos s aberrant activation of toll like receptorTLRHenceby restoring FLNAa ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Pivotal trial of vamorolone in Duchenne muscular dystrophy
SBC: REVERAGEN BIOPHARMA, INC. Topic: NINDSAbstract ReveraGen BioPharma is a clinical stage drug development company that is developing vamoroloneVBPa first in class dissociative steroidal drugThe initial indication being tested is Duchenne muscular dystrophyDMDwhere vamorolone holds promise for retaining or increasing efficacy of glucocorticoidswhile reducing adverse effectsbone fragilitystunting of growthweight gaininsulin resistanceReve ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
TB Diagnostics at the Point of Care
SBC: AKONNI BIOSYSTEMS INC Topic: NIAIDABSTRACT Tuberculosis ranks in the top ten worldwide cause of death and now ranks ahead of HIV, making it the number one infectious disease killer. Perhaps, most alarming is the global prevalence of multidrug-resistant TB (MDR- TB) and extensively drug-resistant TB (XDR-TB): more than 5% of new TB cases are MDR-TB and 10% of these have XDR-TB. And, the number of enrolled XDR-TB cases has grown fro ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Commercialization of an Ultrasound-guided Vascular Access Device
SBC: PERCEPTIVE NAVIGATION LLC Topic: NHLBIPROJECT SUMMARY Safe and reliable access to major blood vessels and internal organs will be beneficial to patients with cardiovascular and cardiothoracic diseases. An interventional catheter with forward-viewing ultrasound imaging capability will be developed to enable image-guided access to blood vessels and internal organs. Phase 1 and 2 experiments demonstrate feasibility of building a high res ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
sHLA Protein Chip
SBC: GENOMICS USA, INC. Topic: NIAIDAbstract: “sHLA Protein Chip” The class I [A, B, C] and class II HLA proteins [DRB1, DQ, DP] comprise the heart of the inducible human immune system. For organ, marrow and stem cell transplantation, the development of serum-born antibodies against one or more of those many HLA proteins comprises the best and earliest test for transplant rejection. Because of the enormous medical importance of ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Automating mosquito microdissection for a malaria PfSPZ vaccine
SBC: SANARIA INC. Topic: RABSTRACTThe global death toll from Malaria is estimated to be upwards ofpeople each yearwith more thanchildren succumbing every dayPlasmodium falciparumPfSporozoiteSPZbased vaccines are the only intervention in humansproven to induce robusthigh levelandgtand long lastingat leastmonthsprotective efficacy against malariaforming the basis of Sanaria s unique technology platform of asepticpurifiedcryo ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Development and Evaluation of Video-Based Directly Observed Therapy for Office-Based Treatment of Opioid Use Disorders with Buprenorphine
SBC: EMOCHA MOBILE HEALTH INC. Topic: NIDAThe Development and Evaluation of of Video Based Directly Observed Therapy for Office Based Treatment of Opioid Use Disorders with Buprenorphine is a project to develop a sustainable scalable and patient centered mobile health mHealth platform comprised of a patient facing mobile application and provider facing web portal for opioid use disorder treatment Methadone clinics are based on a directly ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of Population Level Serotyping Technology and Antibody Profiling for Infectious Pathogens with focus on Influenza and SARS-CoV-2
SBC: ENCODIA INC Topic: 100ABSTRACT The goal of this proposal is to repurpose technology developed for Next-Gen Proteomics to develop a highly-scalable digital serotyping technology for infectious disease analysis, with particular application to influenza and Covid-19. The approach is broadly applicable and should greatly improve upon cost, sensitivity, usability, and throughput of population-level serotyping and greatly im ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
AMBIENT LIGHT ACTIVATABLE OPSIN BASED THERAPY FOR AGE-RELATED MACULAR DEGENERATION
SBC: NANOSCOPE TECHNOLOGIES LLC Topic: NEISevere loss of vision occurs due to age-related macular degeneration (AMD) and approximately 15 million people in the US have some form of AMD, which is expected to double by 2050. Most of the current clinical treatments are primarily focused on slowing down the progression of the disease, as there is neither a cure that can stop the degeneration nor a therapy, other than retinal prostheses, that ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
SBC: 7 Hills Pharma LLC Topic: 102Recent FDA approvals of ipilimumabnivolumaband pembrolizumabwhich target checkpoint receptors cytotoxic T lymphocyte associated antigenCTLAand programmed deathPDhave ushered in a new era of cancer immunotherapy in metastatic melanomaDespite unprecedented overall survival benefits with combination therapythe incidence of complete responses are onlyimmune related adverse eventsirAEsare increasedand ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health